Active Ingredient(s): Faricimab-svoa
FDA Approved: * January 28, 2022
Pharm Company: * GENENTECH INC
Category: Vision / Eye Health

Faricimab, sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).[1][2] Faricimab is the first bispecific monoclonal antibody,[3] to target both vascular endothelial growth factor (VEGF),[1] and angiopoietin 2 (Ang-2) inhibitor.[1] By targeting these pathways, faricimab stabilizes blood vessels in t... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Vabysmo 6 mg/.05ml Intravitreal Injection, Solution
NDC: 50242-096
Genentech, Inc.